1. Taiwan Stocks

  2. •

    Health technology

  3. •

    Medical specialties
Welgene Biotech Co., Ltd.

Welgene Biotech Co., Ltd.

TTPEX:6661
17.30
TWD
+0.15
(+0.87%)
-0.06EPS
419.48MMarket Cap
2014 Y
2015 Y
2016 Y
2017 Y
2018 Y
2019 Y
2020 Y
2021 Y
2022 Y
2023 Y
2024 Y
2025 Y
TTM
Revenue per Share
24.66
17.33
13.44
15.73
18.57
20.16
19.23
13.54
13.81
12.04
13.84
16.13
16.9
Basic EPS, GAAP
1.93
1.33
0.2
1.14
1.37
1.49
1.44
0.59
0.41
-0.11
0.05
0.06
-0.07
Free Cash Flow per Basic Share
0.15
-0.96
0.12
1.14
1.91
3.7
1.73
0.3
1.05
-1.21
2.2
-0.29
-4.34
Dividend per Share
2.13
- -
- -
0.18
0.29
1.26
1.34
1.11
0.48
0.18
- -
- -
- -
Book Value per Share
5.51
9.64
9.83
10.79
11.9
12.1
12.2
13.3
13.03
12.53
12.35
12.07
11.72
Tangible Book Value per Share
5.51
9.58
9.72
10.7
11.83
12.01
12.13
13.25
13
12.51
12.35
12.04
11.02
Basic Weighted Avg Shares
11
16
21
21
21
21
21
23
23
23
23
23
24
Sales/Revenue/Turnover
270
277
278
326
384
417
398
313
322
281
323
376
399
Operating Margin (%)
-7.59
4.76
5.08
9.01
10.15
9.4
9.16
4.7
4.93
-1.73
-0.22
0.02
-0.72
Depreciation Expense
5
7
7
8
8
8
18
19
19
27
29
28
31
Net Income, GAAP
21
21
4
24
28
31
30
14
10
-3
1
1
-2
Effective Tax Rate (%)
8.1
8.89
48.51
18.3
23.63
22.52
19.82
17.43
29.58
- -
43.52
3.14
- -
Profit Margin (%)
7.81
7.68
1.47
7.26
7.37
7.39
7.48
4.38
2.97
-0.94
0.34
0.35
-0.41
Working Capital
87
169
175
184
191
172
169
227
197
178
187
199
146
LT Debt
9
6
4
2
- -
22
11
- -
27
119
96
171
220
Total Equity
114
200
204
224
247
251
253
310
304
300
296
286
278
Return on Invested Capital (%)
- -
5.99
2.94
9.57
11.2
10.5
9.74
3.87
3.52
- -
-0.06
0.06
- -
Return on Capital (%)
- -
11.21
1.92
9.78
11.05
11.2
10.5
4.56
2.83
- -
0.72
1
- -
Return on Common Equity (%)
- -
13.58
2.03
11.08
12.07
12.43
11.84
4.87
3.11
-0.89
0.38
0.47
-0.59

Capital Structure

TWD

•

in mil. unless spec.
Dec'25
Mar'26
Jun'26
ST Debt
55
57
61
LT Borrowings
141
134
197
LT Finance Leases
30
27
23
Preferred Equity and Hybrid Capital
- -
- -
- -
Shares Outstanding
23
23
23
Market Capitalization
433
433
419

Working Capital

TWD

•

in mil. unless spec.
Dec'25
Mar'26
Jun'26
Total Current Assets
364
302
307
Cash, Cash Equivalents & STI
269
204
202
Accounts Receivable, Net
45
40
40
Inventories
39
46
54
Total Current Liabilities
164
154
161
Payables & Accruals
- -
- -
- -
ST Debt
55
57
61
Deferred Revenue
- -
- -
- -

Growth Rates

TWD

•

in mil. unless spec.

(avg. rate of change)

10 years
5 years
1 year
Total Equity
3.92%
2.94%
-3.27%
Free Cash Flow
38.88%
-86.65%
-113.21%
Net Income, GAAP
8.85%
-66.73%
20.14%
Sales/Revenue/Turnover
3.95%
0.03%
16.55%
Total Cash Common Dividend
- -
- -
- -

Quarterly Revenue

TWD

•

in mil. unless spec.

Year

Q1
Q2
Q3
Q4
FY
2024
68
76
90
88
323
2025
78
90
110
98
376
2026
84
107
- -
- -
- -

Quarterly Earnings Per Share

TWD

•

in mil. unless spec.

Year

Q1
Q2
Q3
Q4
FY
2024
-0.24
-0.02
0.33
-0.01
0.05
2025
-0.2
-0.02
0.3
-0.03
0.06
2026
-0.27
-0.07
- -
- -
- -

Quarterly Dividends Per Share

TWD

•

in mil. unless spec.

Year

Q1
Q2
Q3
Q4
FY
2024
- -
- -
- -
- -
- -
2025
- -
- -
- -
- -
- -
2026
- -
- -
- -
- -
- -

Company Description

Company Profile APIChatGPT
CEO
Fu Chien Chen
Full Time Employees
80
Sector
Health technology
Industry
Medical specialties
Address
No. 3, Yuanyuan Street Taipei TP Taiwan 11503
IPO Date
Jan 27, 2021
Website
welgene.com.tw
Similar Companies
Intuitive Surgical, Inc. (NASDAQ:ISRG)
Boston Scientific Corporation (NYSE:BSX)
Thermo Fisher Scientific Inc (NYSE:TMO)
Illumina, Inc. (NASDAQ:ILMN)
Abbott Laboratories (NYSE:ABT)
GRAIL, Inc. (NASDAQ:GRAL)
Business
Welgene Biotech Co., Ltd. (6661.TWO) provides genetic testing services and biotechnology products in Taiwan. The company offers research services including next-generation sequencing (NGS), DNA microarray analysis, real-time quantitative PCR (qPCR) verification, nucleic acid extraction, proteomics analysis, bioinformatics services, and third-generation PacBio sequencing; it also trades medical equipment and genetic testing reagents as the exclusive distributor for Agilent Technologies' Genomics product line in Taiwan, alongside products from Guardant, Somalogic, Epigenetek, and Ops Diagnostics. Welgene Biotech serves academic research units, hospitals, biotechnology companies, and clinical applications such as prenatal genetic screening developed in partnership with Changhua Christian Hospital. Founded in 2003 and headquartered at 12F, No. 3, Yuanyuan Street, Nangang District, Taipei City, Taiwan, the company operates primarily in the domestic Taiwanese market with ISO 17025-accredited laboratories focused on high-throughput genomic technologies.